Asthma study testing PA9159 inhaled spray
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests an inhaled asthma medication, PA9159, in adults with stable or mild-to-moderate asthma. It aims to see if the drug improves lung function and is safe. You may qualify if you have asthma with some airflow limitation and have not had recent severe flare-ups.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a diagnosis of asthma, either newly diagnosed or from childhood that is now stable without long-term treatment.
- Your lung function test shows a certain level of airflow limitation (FEV1 between 60% and 85% of predicted).
- You have had a positive test for reversible airway obstruction in the past year, such as an increase in FEV1 after using a rescue inhaler, or a positive bronchial challenge test, or significant daily variation in peak flow readings.
- You do not have other serious lung diseases like COPD, bronchiectasis, or lung fibrosis that are more significant than your asthma.
- You are not pregnant, breastfeeding, or planning pregnancy during the trial, and you do not smoke or recently quit smoking (less than 1 year) or have a heavy smoking history.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new inhaled medicine called PA9159 for adults with moderate asthma. It compares the medicine to a placebo to see if it safely improves breathing and controls asthma symptoms.
This trial tests whether a new inhaler (CHF5993) works as well as the current standard for adults with mild to moderate asthma. It compares how well the medicine controls asthma and opens airways.
This study checks whether a new albuterol inhaler works the same way as a reference inhaler in adults with stable, mild asthma. It may help you (and others) by confirming that the inhaler delivers the right effect and is safe to use.
This Phase 2 trial tests whether FB825 can improve symptoms and safety in adults with moderate-to-severe allergic asthma. It is mainly for people whose asthma is not well controlled despite regular inhaler treatment.
This study tests an investigational medicine called PF-07275315 for people with moderate-to-severe asthma that is not well controlled with current treatments. The goal is to see if it can reduce asthma attacks and improve breathing.
This study tests a new three-part asthma inhaler (CHF 5993) in people whose asthma isn't well-controlled even though they're already using two standard asthma medicines together. The goal is to see if adding this new medicine helps control asthma better.
Hear when a new Bronchial Asthma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.